Zastaprazan (JAQBO) for erosive GERD study
Part of Digestive system clinical trials.
This study is testing a new stomach acid reducer medication (zastaprazan, also called JAQBO) in people with erosive GERD, a condition where acid reflux has damaged the esophagus. It tracks how well the medicine works in everyday medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years of age or older
- You have been diagnosed with erosive reflux disease (ERD) — a type of heartburn that has caused damage to your esophagus
- You have no known allergies to the study drug or its ingredients
- You are not currently taking the HIV or hepatitis medications atazanavir, nelfinavir, or rilpivirine
- You are not pregnant (or could become pregnant), and you are not breastfeeding
- You do not have certain rare genetic conditions like galactose intolerance or lactase deficiency
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment for nighttime heartburn caused by GERD, a condition where stomach acid damages the esophagus. It is for adults who have had nighttime heartburn for more than 3 months and have been diagnosed with erosive GERD.
This trial tests if a new stomach acid medicine (Zastaprazan) affects how well clopidogrel works in heart patients who have had a stent placed. It aims to help people who need both clopidogrel and a stomach acid drug after a procedure.
This trial tests a new medicine called anaprazole for people with moderate to severe reflux esophagitis (chronic heartburn and damage to the food pipe). It compares anaprazole to a standard treatment to see which works better and is safer.
This trial tests a new medicine, JP-1366, for people with non-erosive GERD (heartburn and acid reflux without visible damage to the esophagus). The goal is to see if it helps control symptoms better than a placebo.
This study looks at how well and how safely the drug tegoprazan works for people with gastroesophageal reflux disease (GERD). It may help if you have symptoms like heartburn or acid reflux.
This trial tests a new medication, JP-1366, for people with reflux esophagitis (damage to the esophagus from stomach acid). It aims to see if the drug is safe and effective at healing the esophagus and relieving symptoms like heartburn and regurgitation.
Hear when a new Erosive Gastroesophageal Reflux Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.